Podcasts about hiv infection

Un nouvel épisode du Pharmascope est maintenant disponible! Dans de ce 136ème épisode, Nicolas, Isabelle et un invité discutent de la prophylaxie pré-exposition au VIH dans diverses situations à risque.  Les objectifs pour cet épisode sont : Résumer et comparer les modalités de prise en charge de la PrEP Identifier les patients pouvant bénéficier de la PrEP Discuter des avantages et des risques associés à la prise de la PrEP   Ressources pertinentes en lien avec l'épisode Baril JG et coll. La prophylaxie préexposition au virus de l'immunodéficience humaine : Guide pour les professionnels de la santé du Québec. Ministère de la santé et des services sociaux. Janvier 2019. Disponible, en ligne. US Public Health Services.Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update. A Clinical Practice Guideline. 2021. Disponible, en ligne. Grant RM et coll; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. Grant RM et coll; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820-9. McCormack S et coll. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60. Molina JM et coll; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237-46. Baeten JM et coll; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410. Choopanya K et coll; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.

  Thabo Shole -Mashao, in for Clement Manyathela, speaks to Christine Muhigana, a representative of Unicef in South Africa about their recent report on high HIV infections among children and adolescents.See omnystudio.com/listener for privacy information.

Young girls and orphans in the North-West province are at higher risk of HIV infection. This according to recent findings from HIVSA. The study found that the Southern and Bojanala regions have the highest prevalence in the province. For more on this Elvis Presslin spoke to HIVSA CEO, Yashmita Naidoo

Un nouvel épisode du Pharmascope est maintenant disponible! Dans de ce 136ème épisode, Nicolas, Isabelle et un invité discutent de la prophylaxie pré-exposition au VIH dans diverses situations à risque.  Les objectifs pour cet épisode sont les suivants: Résumer et comparer les modalités de prise en charge de la PrEP Identifier les patients pouvant bénéficier de la PrEP Discuter des avantages et des risques associés à la prise de la PrEP Ressources pertinentes en lien avec l'épisode Baril JG et coll. La prophylaxie préexposition au virus de l'immunodéficience humaine : Guide pour les professionnels de la santé du Québec. Ministère de la santé et des services sociaux. Janvier 2019. Disponible, en ligne. US Public Health Services.Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2021 Update. A Clinical Practice Guideline. 2021. Disponible, en ligne. Grant RM et coll; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. Grant RM et coll; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820-9. McCormack S et coll. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60. Molina JM et coll; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237-46. Baeten JM et coll; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410. Choopanya K et coll; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.

Dr Saloni Surah is a published author of her first children's book Flora Investigates: The Case Of The Missing Gold eggs. This is a funny, zany book for 5-9 year olds. Her second book The Last Fairy Guardian is due out early next year. She is also a HIV & sexual health consultant and has a PhD on HIV Infection & drug use. She has worked with marginalised populations from all over the world. Working in her particular area of medicine, Dr Surah became acutely aware of the mind-body connection with regards to ill-health and wellbeing. She has an active interest in meditation, self-development and other healing modalities and also works a spiritual coach using EFT and energy work. SummaryIn this episode, Saloni discusses her journey from being a doctor in the medical field to becoming a coach and author. She shares her experiences with alternative practices such as tapping and crystal work, and how they influenced her coaching approach. Saloni also explores the collective themes and energy she has observed, including the shift in gender roles and the need for men to catch up in personal growth. She delves into the importance of ancestral healing and the impact of financial trauma and programming. Saloni emphasizes the need for clarity and open discussion to start the journey of ancestral healing. In this conversation, Saloni Surah and Jen discuss the power of intention and the different ways to access ancestral money control. They explore various modalities for self-discovery, including meditation, automatic writing, and journaling. They emphasize the importance of individual approaches and finding what works best for each person. They also discuss the challenges of being a coach and the journey of discovering true purpose and passion. The conversation touches on the topics of boundaries, grief, transparency, and the meaning of life as love and joy.Takeaways· Setting intentions and opening space can lead to the manifestation of desired outcomes.· There are various ways to access and work through ancestral money control, including tapping into the Akashic records and ancestral healing.· Different modalities, such as meditation, automatic writing, and journaling, can be used for self-discovery and personal growth.· Finding the right meditation practice and individual approach is essential, as there is no one-size-fits-all method.· Being a coach or facilitator involves wearing many hats and navigating challenges, but it is a fulfilling journey of helping others discover their true purpose and passion.· Transparency and breaking down stigmas around personal struggles and grief are important for creating authentic connections.· Writing children's books can be a way to inspire and empower young readers while embracing magic and imagination.· The meaning of life is often found in love and joy, as well as connection and community· Plus so much moreTo get in touch with Saloni and purchase her books, her website is https://salonisurah.comTo know more about the work that Jen does, head to the website: www.jenhamilton.coach Don't forget to follow your host, Jen, on Instagram at www.instagram.com/jenhamiltonofficial and the podcast at www.instagram.com/enlifened_podcast This podcast is for educational and entertainment purposes only. The host and her guests claims no responsibility to any person or entity for any liability, loss, or damage caused or alleged to be caused directly or indirectly as a result of the use, application, or interpretation of the information presented herein.

This week, Marianna sits down with John Faragon to talk about new guidelines released from the U.S. Department of Health & Human Services about statin use. Tune to learn all about them and how this relates to HIV care. --Episode Resources: Pitavistatin to Prevent Cardiovascular Disease in HIV Infection: https://www.nejm.org/doi/full/10.1056/NEJMoa2304146Guidelines for the Use of Antiretroviral Agents in Adults & Adolescents with HIV: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/statin-therapy-people-hiv--Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=BHN6412)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

PNG struggle to bring HIV infection rates down.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers HIV/AIDS psychiatry with special guests from two international settings to provide complementary perspectives on HIV psychiatry. Dr. Adriana Carvalhal, HIV Psychiatrist and Staff Psychiatrist at Scarborough Health Network in Canada and Dr. Leigh Van Den Heuvel, Psychiatrist and Associate Professor in the Department of Psychiatry, at Stellenbosch University in South Africa. The learning objectives for this episode are as follows:  By the end of this episode, you should be able to… Understand the unique mental health needs of people living with HIV and the bidirectional relationship between HIV and mental health Identify HIV-specific mental health disorders and how to screen for these conditions Outline the overall approach to treatment for HIV patients with mental health disorders Guests: Dr. Adriana Carvalhal and Dr Leigh Van Den Heuvel Produced by: Saja Jaberi (MD), Kate Braithwaite (MD) and Gaurav Sharma (PGY5) Hosts: Kate Braithwaite (MD) and Gaurav Sharma (PGY5) Audio editing by: Gaurav Sharma (PGY5) Show notes by: Saja Jaberi (MD) and Gaurav Sharma (PGY5) Conflicts of Interest: Neither of our guests nor hosts have declared any conflicts of interest related to this topic. Generic names are used for all medications referenced. Contents: Introduction - 0:19 Learning objectives - 3:52 The bidirectional relationship between HIV and psychiatric illness - 4:24 Prevalence of psychiatric illness in HIV - 9:56 Screening for psychiatric illness in HIV populations - 12:11 HIV Associated Neurocognitive Disorder (HAND) - 19:27 Diagnostic Criteria - 20:19 Clinical Presentation & Etiology - 23:03 Risk Factors - 26:56 Screening Tools - 32:06 Treatment - 36:59 HIV Psychiatry case example - 39:48 Navigating the differential diagnosis - 41:44 Initial management & addressing comorbidities - 44:30 Drug-drug interactions between antiretroviral and psychiatric medications - 48:04 Review of learning objectives & final thoughts - 52:04 Outro - 55:55   Resources: Clinical Care Guidelines for Adults and Adolescents Living with HIV in Ontario, Canada (occguidelines.com) Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets, 2020 - Canada.ca   HIV and Clinical Depression  https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Professional-Topics/HIV-Psychiatry/FactSheet-Anxiety-2012.pdf  https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Professional-Topics/HIV-Psychiatry/FactSheet-CognitiveDisorder-2012.pdf  International HIV Dementia Scale (IHDS) - Mental Health Screening - National HIV Curriculum (uw.edu)/ Liverpool HIV Interactions (hiv-druginteractions.org) References: Angelovich TA, Churchill MJ, Wright EJ, Brew BJ. New Potential Axes of HIV Neuropathogenesis with Relevance to Biomarkers and Treatment. Curr Top Behav Neurosci. 2021;50:3-39. doi: 10.1007/7854_2019_126. PMID: 32040843. Angelovich TA, Churchill MJ, Wright EJ, Brew BJ. New Potential Axes of HIV Neuropathogenesis with Relevance to Biomarkers and Treatment. Curr Top Behav Neurosci. 2021;50:3-39. doi: 10.1007/7854_2019_126. PMID: 32040843. Awori V, Mativo P, Yonga G, Shah R. The association between asymptomatic and mild neurocognitive impairment and adherence to antiretroviral therapy among people living with human immunodeficiency virus. South Afr J HIV Med. 2018 Apr 12;19(1):674. doi: 10.4102/sajhivmed.v19i1.674. PMID: 29707383; PMCID: PMC5913780. Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA. A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis. 2016 Sep 1;63(5):687-693. doi: 10.1093/cid/ciw399. Epub 2016 Jun 19. PMID: 27325690; PMCID: PMC4981762. Clinical Care Guidelines for Adults and Adolescents living with HIV in Ontario, Canada. Clinical Care Guidelines for Adults and Adolescents Living with HIV in Ontario, Canada (occguidelines.com) Core Concepts - Screening for Mental Health Conditions - Basic HIV Primary Care - National HIV Curriculum (uw.edu) Cysique LA, Casaletto KB, Heaton RK. Reliably Measuring Cognitive Change in the Era of Chronic HIV Infection and Chronic HIV-Associated Neurocognitive Disorders. Curr Top Behav Neurosci. 2021;50:271-298. doi: 10.1007/7854_2019_116. PMID: 31559600. EACS Guidelines version 11.1, October 2022. Joska JA, Witten J, Thomas KG, Robertson C, Casson-Crook M, Roosa H et al. A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa. AIDS and behavior. 2016 Aug 1;20(8):1621-1631. doi: 10.1007/s10461-016-1316-y Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis. 2019;11(4):372-387. doi: 10.1007/s40506-019-00203-7. Epub 2019 Nov 16. PMID: 33380904; PMCID: PMC7758219. Robbins RN, Scott TM, Gouse H, Marcotte TD, Rourke SB. Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity. Curr Top Behav Neurosci. 2021;50:429-478. doi: 10.1007/7854_2019_117. PMID: 32677005. Rubin LH, Maki PM. Neurocognitive Complications of HIV Infection in Women: Insights from the WIHS Cohort. Curr Top Behav Neurosci. 2021;50:175-191. doi: 10.1007/7854_2019_101. PMID: 31396894. Southern African HIV Clinicians Society. Management of mental health disorders in HIV-positive patients. S Afr J HIV Med 2013; 14(4): 155 - 165  Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2021 Dec 6;73(11):e3572-e3605. doi: 10.1093/cid/ciaa1391. Erratum in: Clin Infect Dis. 2021 Dec 08;: Erratum in: Clin Infect Dis. 2022 Nov 30;75(11):2052. PMID: 33225349. Turjanski, N., & Lloyd, G. (2005). Psychiatric side-effects of medications: Recent developments. Advances in Psychiatric Treatment, 11(1), 58-70. doi:10.1192/apt.11.1.58 Wang Y, Liu M, Lu Q, Farrell M, Lappin JM, Shi J, Lu L, Bao Y. Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis. Neurology. 2020 Nov 10;95(19):e2610-e2621. doi: 10.1212/WNL.0000000000010752. Epub 2020 Sep 4. PMID: 32887786.   CPA Note: The views expressed in this podcast do not necessarily reflect those of the Canadian Psychiatric Association. For more PsychEd, follow us on Twitter (@psychedpodcast), Facebook (PsychEd Podcast), and Instagram (@psyched.podcast). You can provide feedback by email at psychedpodcast@gmail.com. For more information, visit our website at psychedpodcast.org.

Leaving home is never easy—especially when discrimination, xenophobia, and cultural barriers await you in your new destination. In this episode, Zero Hour™ speaks with two leaders who are working to not only ease the transition for migrants and displaced people, but to also connect them with vital HIV services and resources. Our guests are: Denis Onyango, a grassroots activist who organizes HIV testing, prevention, and peer support services through his role as Programs Director for the Africa Advocacy Foundation. He reflects on how losing his brother and three sisters to AIDS spurred his focus on HIV activism, as well as the harsh realization that the care they went without was widely available in other parts of the world. Isjed Hussain, founder of the Prisma Group Foundation, which supports bicultural and Muslim LGBTQ people in the Netherlands. They explain how Prisma helps refugees to navigate the asylum process and how they assist refugees living with HIV. This podcast was created and fully funded by Gilead Sciences, Inc. GILEAD, the GILEAD logo, and the & design are trademarks of Gilead Sciences, Inc. © 2023 Gilead Sciences, Inc. All rights reserved. US-UNBC-1760 Date of Preparation August 2023. Correction: Guest states that a study took place with 3000 participants in 10 countries. In actuality, the study took place in 9 countries with 2009 participants. References: Alvarez-Del Arco D. et al, AIDS, 2017; 31(14):1979-1988. Accessed August 23, 2023 European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2021 – 2020 data. Stockholm: ECDC; 2021. Accessed July  15, 2023. Available at: https://www.ecdc.europa.eu/en/publications-data/hiv-aids-surveillance-europe-2021-2020-data European Centre for Disease Prevention and Control. HIV and migrants. Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2018 progress report. Stockholm: ECDC; 2019. Accessed July 15, 2023. Available at: https://www.ecdc.europa.eu/en/publications/hiv-migrants-monitoring-implementation-dublin-declaration-2018-progress-report Frescura L, Godfrey-Faussett P, Feizzadeh A A, El-Sadr W, Syarif O, Ghys PD; on behalf of the 2025 testing treatment target Working Group. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One. 2022 Aug 4;17(8):e0272405. doi:10.1371/journal.pone.0272405. Gbadamosi SO, Trepka MJ, Dawit R, Jebai R, Sheehan DM. A Systematic Review and Meta-analysis to Estimate the Time from HIV Infection to Diagnosis for People with HIV. AIDS Rev. 2022 Mar 1;24(1):32-40. doi: 10.24875/AIDSRev.21000007. PMID: 34077404; PMCID: PMC8636511. Accessed August, 23 2023 US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. March 2023. Accessed July 15, 2023. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf

Drs Michael S. Saag and Rajesh Gandhi discuss HIV and Antiretroviral Therapy Guidelines. When to begin treatment, which treatment to choose, and how to treat the whole person, not just the HIV. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986509). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview Zidovudine (Rx) https://reference.medscape.com/drug/retrovir-zdv-zidovudine-342639 ddI and d4T Plus Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/11364012/ HIV-Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/9562584/ Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection https://pubmed.ncbi.nlm.nih.gov/26192873/ Early Symptomatic HIV Infection https://reference.medscape.com/article/211873-overview IAS-USA https://www.iasusa.org/ Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel https://pubmed.ncbi.nlm.nih.gov/36454551/ Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs https://pubmed.ncbi.nlm.nih.gov/33572956/ Dolutegravir (Rx) https://reference.medscape.com/drug/tivicay-tivicay-pd-dolutegravir-999861 Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) https://www.medscape.com/viewarticle/941921_4 Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/ Tenofovir DF (Rx) https://reference.medscape.com/drug/viread-tenofovir-df-342633 Tenofovir AF (Rx) https://reference.medscape.com/drug/vemlidy-tenofovir-af-1000007 Abacavir (Rx) https://reference.medscape.com/drug/ziagen-abacavir-342600 HLA B 5701 Testing https://www.ncbi.nlm.nih.gov/books/NBK560797/ Dolutegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/juluca-dolutegravir-rilpivirine-1000216 Efficacy and Safety of Dolutegravir-Rilpivirine for Maintenance of Virological Suppression in Adults With HIV-1: 100-Week Data From the Randomised, Open-Label, Phase 3 SWORD-1 and SWORD-2 Studies https://pubmed.ncbi.nlm.nih.gov/31307948/ Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti Cabotegravir/Rilpivirine: The Last FDA-Approved Drug to Treat HIV https://pubmed.ncbi.nlm.nih.gov/35596583/ Anticipating and Managing Drug Interactions: Pharmacokinetics of Long-Acting HIV Treatment and Prevention Formulations https://www.medscape.com/viewarticle/986504 Mpox Vaccination Basics https://www.cdc.gov/poxvirus/mpox/vaccines/index.html COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/summary-recommendations/ Mpox in People With Advanced HIV Infection: A Global Case Series https://pubmed.ncbi.nlm.nih.gov/36828001/ Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient Setting https://www.medscape.com/viewarticle/986506

Anthony speaks with authors Dr Burtle, Dr Marsh, and Dr Matin about the management of patients who have HIV on presentation to the ICU. They discuss common reasons for admission, diagnostic and therapeutic challenges, and the impact of the difference in chronic disease management now compared with 30 years ago.

You do it. Your parents did it. Even the Puritans did it…so why are we so puritanical when it comes to talking about sex? In this episode, we're bringing it all out of the bedroom and discussing how openly talking about sex is a necessary first step to talking about HIV. Sex positivity, health exploration, eliminating stigmas and taboos—they all start here, with the birds and the bees.  Our guests are:  Nathan Hale Williams, an actor, film and television producer, and entertainment producer known for writing and co-directing the film 90 Days, as well as directing the 2021 short film adaptation of All Boys Aren't Blue. He discusses the social challenges that limit critical conversations about HIV and his tactics for authentically portraying the experiences of people living with HIV in his work.  Dr. Cedric Pulliam, the Director of Global Public Policy at Prevention Access Campaign, where he works to advance global LGBTQ+ and human rights policies. He explains the impact U=U can have on international HIV strategy and the intrinsic relationship between sexual health and health equity.  Goody Howard, a world-renowned sexologist who normalizes sex-positivity through sexual skill workshops and professional development programs. She articulates the roles both men and women must play in sexual health education, as well as how to incorporate pleasure into conversations about safe sex.  This podcast was created and fully funded by Gilead Sciences, Inc. GILEAD, the GILEAD logo, and the & design are trademarks of Gilead Sciences, Inc. © 2023 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-4253 Date of Preparation July 2023.  References:   DHHS. Panel on antiretroviral guidelines for adults and adolescents. Recommendations for the use of antiretroviral agents in adults and adolescents with HIV. Updated March 23, 2023. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed July 20, 2023.  Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240031593. Accessed July 20. 2023.   Ford OG, Rufurwadzo TG, Richman B, et al. Adopting U = U to end stigma and discrimination. J Int AIDS Soc. 2022;25(3):e25891. doi:10.1002/jia2.25891  Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks, challenges and opportunities. J Virus Erad. 2016 Apr 1;2(2):87-93.   CDC. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update – A Clinical Practice Guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed July 20, 2923.  Barré-Sinoussi F, Abdool Karim SS, Albert J, et al. Expert consensus statement on the science of HIV in the context of criminal law. J Int AIDS Soc. 2018 Jul;21(7):e25161. doi:10.1002/jia2.25161.  Apcom.org. Getting to zero: Leveraging U=U for communty empowerment and eliminating stigma. Available at: https://www.apcom.org/getting-to-zero-leveraging-uu-for-community-empowerment-eliminating-stigma/. Accessed July 20, 2023. 

Drs Michael S. Saag and Roger Bedimo discuss weight gain after starting antiretroviral therapy, including risk factors, long-term outcomes, and patients' well-being. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986507). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Weight Gain on INSTI-Based HIV Antiretrovirals https://www.medscape.com/viewarticle/916095#vp_2 Lipodystrophy in HIV Clinical Presentation https://emedicine.medscape.com/article/1082199-clinical Protease Inhibitors' Metabolic Side Effects: Cholesterol, Triglycerides, Blood Sugar, and 'Crix Belly.' Interview With Lisa Capaldini, MD. Interview by John S. James https://pubmed.ncbi.nlm.nih.gov/11364559/ Reduced Survival After Serious Non-AIDS Complications https://www.medscape.com/viewarticle/721773 HIV Protease Inhibitor-Related Lipodystrophy Syndrome https://pubmed.ncbi.nlm.nih.gov/10860898/ Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview Integrase Strand Transfer Inhibitor (INSTI) https://clinicalinfo.hiv.gov/en/glossary/integrase-strand-transfer-inhibitor-insti Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti Strategies to Prevent Weight Gain Among Adults https://pubmed.ncbi.nlm.nih.gov/23638485/ Tenofovir Alafenamide (TAF) Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/35146360/ Associations Between Integrase Strand-Transfer Inhibitors and Cardiovascular Disease in People Living With HIV: A Multicentre Prospective Study From the RESPOND Cohort Consortium https://pubmed.ncbi.nlm.nih.gov/35688166/ Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s https://pubmed.ncbi.nlm.nih.gov/34117756/ Is Tenofovir Disoproxil Fumarate Associated With Weight Loss? https://pubmed.ncbi.nlm.nih.gov/34848586/ Switching From Boosted PIs to Dolutegravir Decreases Soluble CD14 and Adiponectin in High Cardiovascular Risk People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34120186/ Adiponectin: A Fat Cell Hormone That Promotes Insulin Sensitivity https://www.medscape.org/viewarticle/438373 Glucagon-like Peptide-1 Analogues: An Overview https://pubmed.ncbi.nlm.nih.gov/23869296/ Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV https://pubmed.ncbi.nlm.nih.gov/31339677/ Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC+DTG and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG https://pubmed.ncbi.nlm.nih.gov/36519389/ The ADVANCE Study: A Groundbreaking Trial to Evaluate a Candidate Universal Antiretroviral Regimen https://pubmed.ncbi.nlm.nih.gov/28538284/

Drs Michael S. Saag and Monica Gandhi discuss COVID-19 and the impact this pandemic has had on patients diagnosed with HIV, including vaccines, boosters, and patients who are older or have chronic comorbid conditions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986505). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Coronavirus Disease 2019 (COVID-19) https://emedicine.medscape.com/article/2500114-overview HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview HIV https://www.who.int/news-room/fact-sheets/detail/hiv-aids Molnupiravir, an Oral Antiviral Treatment for COVID-19 https://pubmed.ncbi.nlm.nih.gov/34159342/ Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients https://pubmed.ncbi.nlm.nih.gov/34914868/ Molnupiravir for the Treatment of COVID-19 in Immunocompromised Participants: Efficacy, Safety, and Virology Results From the Phase 3 Randomized, Placebo-Controlled MOVe-OUT Trial https://pubmed.ncbi.nlm.nih.gov/36648627/ Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults With COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): An Open-Label, Platform-Adaptive Randomised Controlled Trial https://pubmed.ncbi.nlm.nih.gov/36566761/ Paxlovid https://pubmed.ncbi.nlm.nih.gov/35138785/ Protease Inhibitors as Promising Weapons Against COVID-19: Focus on Repurposing of Drugs Used to Treat HIV and HCV Infections https://pubmed.ncbi.nlm.nih.gov/34727849/ A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19 https://pubmed.ncbi.nlm.nih.gov/32187464/ Tenofovir Disoproxil Fumarate and Coronavirus Disease 2019 Outcomes in Men With HIV https://pubmed.ncbi.nlm.nih.gov/35848570/ Development of COVID-19 Vaccines–An Unanticipated Moon Shot Achieved at Warp Speed https://pubmed.ncbi.nlm.nih.gov/36689231/ Emerging Viral Diseases From a Vaccinology Perspective: Preparing for the Next Pandemic https://pubmed.ncbi.nlm.nih.gov/29199281/ A Bivalent Omicron-Containing Booster Vaccine Against Covid-19 https://pubmed.ncbi.nlm.nih.gov/36112399/ New Boosters Are Here! Who Should Receive Them and When? https://pubmed.ncbi.nlm.nih.gov/36354037/ Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients https://pubmed.ncbi.nlm.nih.gov/35653428/ Nirmatrelvir Use and Severe Covid-19 Outcomes During the Omicron Surge https://pubmed.ncbi.nlm.nih.gov/36001529/

In this episode, Darcey Wooten, MD, discusses updated guidance and rationale for monitoring for new HIV infections in people receiving long-acting PrEP, including:Testing both Ag/Ab and HIV-1 RNASteps to take when a person receiving long-acting PrEP develops a new HIV infectionPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:https://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

Is it rude to ask my partner to get a HIV test? Should I still have kids if I'm HIV+? Are straight people at less risk of HIV infection? What are PeP and PReP pills? Hosted on Acast. See acast.com/privacy for more information.

Rajesh T. Gandhi, MD, director of Harvard University's Center for AIDS Research, talks about recent advances in the treatment and prevention of HIV and discusses HIV in the context of COVID-19 and monkeypox infections. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ. Related Content: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults Ending the HIV Epidemic Anthony Fauci, MD: Working to End HIV/AIDS

Rob Swan is a member of New Brunswick's gay community. Charles Furlotte is an assistant professor at Saint Thomas University.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 13, 2022, issue.

Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963242). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources AIDS Clinical Trials Group (ACTG) https://www.niaid.nih.gov/research/aids-clinical-trials-group Cabotegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156 Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/ Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside Initiation of Long-acting Cabotegravir Plus Rilpivirine as Direct-to-Injection or With an Oral Lead-in in Adults With HIV-1 Infection: Week 124 Results of the Open-Label Phase 3 FLAIR Study https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00184-3/fulltext Lenacapavir (Pending FDA Approval) https://reference.medscape.com/drug/lenacapavir-4000240 Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir https://www.gilead.com/news-and-press/company-statements/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir Drug Database: Lenacapavir https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/health-professional Doravirine Prescribing Information https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults https://actgnetwork.org/studies/actg-a5357-a-study-of-long-acting-cabotegravir-plus-vrc01ls-to-maintain-viral-suppression-in-hiv-1-infected-adults/ Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV https://clinicaltrials.gov/ct2/show/NCT04334915?term=ACTG+5363&draw=2&rank=1 Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189692/ Evusheld (Formerly AZD7442) Long-acting antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19 https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html

Back in our March 2020 episode, This is Hope, we spoke with Dr. Larissa May about HIV screening in the ED. Screening programs, along with education and other resources, is making a difference, but there are still tens of thousands of new HIV cases in the U.S. each year, and probably 1-2 million new infections annually worldwide. There are clinical trials in progress studying potential HIV vaccines, which is exciting, but a widely available vaccine is still many years away. Luckily, we DO have a safe and effective way to help prevent new infections and transmission - pre-exposure prophylaxis (PrEP). Dr. Michael Casner joins us to share his expertise in all things PrEP, so we can help our patients stay safe and healthy.  Do you talk to your patients about PrEP? Does your ED have a way to connect patients with resources to obtain PrEP? Share your experience with us on social media, @empulsepodcast, via email empulsepodcast@gmail.com, or through our website, ucdavisem.com. Then please head over to iTunes and leave us a review. And please pass the word along to your friends and colleagues! ***Please rate us and leave us a review on iTunes! It helps us reach more people.*** Hosts: Dr. Sarah Medeiros, Associate Professor of Emergency Medicine at UC Davis Guest: Dr. Michael Casner, Emergency Physician at Mount Sinai and Holy Cross hospitals in Chicago, IL, and part-time Emergency Medicine Faculty at the University of Missouri, Kansas City, MO.  Resources: HIV.gov PrEP information and resources Ready, Set, PrEP - medication at no cost for those who qualify Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update—A Clinical Practice Guideline  Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428-2438. doi:10.1016/S0140-6736(19)30418-0 Support Dr. Casner's team in the AIDS/LifeCycle! *** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services. Dr Mike Casner

In 1999, “The Yin & Yang of HIV” was published by Dr Valendar Turner and investigative journalist Andrew McIntyre under the guidance of Eleni Papadopulos-Eleopulos. Eleni was the founder and leader of The Perth Group and her work has influenced virtually all of us today who question the HIV/AIDS dogma. Here is Part 3 of the essay “The Diagnosis of “HIV” Infection”, which is just as relevant today as when it was first written…

FAUCI WALKS BACK CLAIMS THAT THE PANDEMIC IS OVER. AMERICAN EDUCATION FAILURE? COVID VACCINE AND HIV INFECTION. WITH JERRY MALCOLM, GRANT CARDONE, JOHN LEGERE, AND JONATHAN BING. Our live show gives our listeners the chance to actually hear us perform and even influence the show and gives us the unique opportunity to create a bond with our already captive listeners. The instant feedback – the laughs, the gasps, that sense of connection. They're coming to our show to feel part of a conversation and voice their opinion every time we record a podcast episode. The people that attend our live podcast show have a great time, tell their friends and family and attract some very powerful champions of each spirited DEBATE The NEWS episode. Here at DTN, We DEBATE The News! We Allow You To Present Your Interpretation On Today's Local, National, & World News Topics. Spirited & Informed Discussions Are Encouraged. Engage and Sharpen Your Mind with Intellectual Combat! Live On the Clubhouse APP: https://www.debatethenews.com/jointheclub (Clubhouse Link) M-F 6:00 PM - 9:00 PM EST / 3:00 PM - 6:00 PM PST Meet the Host(s): https://www.debatethenews.com/gat (Get Access Tour | MasterClass)

Drs Michael Saag and Constance Benson discuss antiretroviral therapy, maintenance, and switching. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963238). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf AIDS Clinical Trials Group https://actgnetwork.org/ Clarithromycin Therapy for Bacteremic Mycobacterium Avium Complex Disease https://www.acpjournals.org/doi/10.7326/0003-4819-121-12-199412150-00001?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed UC San Diego Medical Center https://healthlocations.ucsd.edu/san-diego/200-w.-arbor-drive-hospital Highlights from the Ryan White Clinical Conference https://www.hiv.gov/blog/long-acting-injectables-hold-promise-maintaining-viral-suppression-and-preventing-hiv Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492356/ Key Considerations and Recommendations for Early (Acute and Recent) HIV Infection https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/early-acute-and-recent-hiv-infection?view=full Rising Rates of Recent Preexposure Prophylaxis Exposure Among Men Having Sex with Men Newly Diagnosed With HIV: Antiviral Resistance Patterns and Treatment Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876422/ Long-acting Cabotegravir Plus Rilpivirine for Treatment in Adults With HIV-1 Infection: 96-week Results of the Randomised, Open-Label, Phase 3 FLAIR Study https://linkinghub.elsevier.com/retrieve/pii/S2352-3018(20)30340-4

Lara Manganaro, INGM, Milan, Italy speaks on "Viral reporters to study HIV infection". This video is part of Course “Flow cytometry: from basic principles to advanced applications-CytoFlow@ICGEB”, an online event 28-30 September 2021. For more informations please visit https://www.icgeb.org.

In this podcast we discuss the reported impact of HIV infection on people who are hospitalised with COVID-19, by reviewing three publications: 1. Outcomes of COVID-19 Related Hospitalization Among People With HIV in the ISARIC WHO Clinical Characterization Protocol: A Prospective Observational Study. Clinical Infectious Diseases, 23 October 2020 (https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021). 2.Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis.Nature, Scientific Reports, 18 March 2021 (https://www.nature.com/articles/s41598-021-85359-3). 3. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS has just been released. WHO Global Clinical Platform, 15 July 2021 (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1605/5937133). STI's Podcast Editor, Dr Fabiola Martin, interviews Prof Anna Maria Garretti, Diseases at the Policlinico Tor Vergata, University of Rome Tor Vergata, Chair of the British HIV Association Vaccination Guidelines Panel, and Editor in Chief of the STI Journal; and Associated Research Professor Dr Paddy Ssentongo, from the Penn State University, Pennsylvania, USA. Read the blog post: https://blogs.bmj.com/sti/2021/09/16/c19-plwh-revisited/

Dr Megan Brundrett visits the studio as we consider the prevention of HIV infection with Pre-Exposure Prophylaxis (PrEP). We explore identification and support of at-risk youth and discuss the benefits, risks and side effects of PrEP medications. We hope you can join us!

Ah, springtime has hit Maed in India and there’s a sweet smell in the air! You get a Phool, you get a Phool, and you get a Phool! No, we’re not fooling you; this mixtape is a bouquet of songs in a variety of colours, meanings and notes. So lay down in this musical meadow and take a big whiff. Song List: Basho ft. Sandeep John - Spacesuit (02:34 - 07:10) Adityan - Lord Labakdas (07:56 - 11:01) Imam Collective - Wanderlust (13:03 - 19:27) Khanvict - Searching For You (20:50 - 23:15) Zeron - Yatra (24:36 - 26:58) Vivek Jha - Cyanide Dream (28:28 - 32:53) Sampriti - Endhaar (33:59 - 38:56) --- The awesome artwork for this episode was designed by Yash Pradhan, a designer & illustrator we love to work with and we’re huge fans of! He has recently launched new line of merchandise that you can check out right here! Also follow him Instagram, Twitter and check out his website here. --- NOTE: A portion of this episode has mentions of addiction. Please take care when listening. If you or someone you love is going through addiction, there is help available. Here are some resources: The Ministry of Social Justice & Empowerment has a 24x7 National Toll-Free Helpline to assist the alcoholic and drug dependent persons, their family members and community at large: 1800-11-0031. The Kripa Foundation, an NGO affiliated with the Union Ministry of Social Justice & Empowerment, working among people afflicted with chemical dependency & HIV Infection, offering in-house rehabilitation programs, out-patient consulting, AA/NA meetings, various types of counselling and therapeutic interventions. Their 24x7 helplines are: +91-022-26405411, +91-022-26433027 & +91-022-26429158. SOSONA (Society Of Service Of Narcotics Anonymous) has online meetings. There are also forums and support groups such as Narcotics Anonymous Recovery Forum & Addiction Recovery Support Group. --- Come be our friend: Facebook @maedinindia Instagram @maedinindia Twitter @maedinindia CREDITS: Host: Mae Twitter: @maebemaebe Instagram: @maemariyam Audio Editor Post: Kartik Kulkarni Producer: Shaun Fanthome and Husein Haveliwala

No episódio de hoje, continuamos a conversa acerca da Conferência anual sobre Retrovírus e Infecções Oportunistas (CROI, março 2021). Ouça aqui, em primeira mão, a opinião de Dr. Eugénio Teófilo e de Dr. Ricardo Correia de Abreu sobre as principais novidades na área do tratamento da infeção por VIH.Dr. Eugénio TeófiloMédico de Medicina Interna e Assistente Hospitalar do Centro Hospitalar Lisboa Central, Hospital dos CapuchosDr. Ricardo Correia de AbreuMédico Infeciologista do Hospital Pedro Hispano da Unidade Local de MatosinhosOlho Clínico é um Podcast da MSD de atualização científica, direcionado exclusivamente a Profissionais de Saúde. O conteúdo do mesmo não tem por objetivo induzir qualquer alteração de comportamento na prescrição ou toma de medicamentos.  PT-NON-00904 04/2021

A Conferência anual sobre Retrovírus e Infecções Oportunistas (CROI, março 2021) acolheu algumas das apresentações e descobertas mais importantes no mundo dos retrovírus humanos e doenças infecciosas, incluindo a infeção por HIV. Junte-se a Dr. Eugénio Teófilo e Dr. Ricardo Correia de Abreu para ouvir, em primeira mão, a sua opinião sobre as principais novidades na área da prevenção da infeção por VIH.Dr. Eugénio TeófiloMédico de Medicina Interna e Assistente Hospitalar do Centro Hospitalar Lisboa Central, Hospital dos CapuchosDr. Ricardo Correia de AbreuMédico Infeciologista do Hospital Pedro Hispano da Unidade Local de MatosinhosOlho Clínico é um Podcast da MSD de atualização científica, direcionado exclusivamente a Profissionais de Saúde. O conteúdo do mesmo não tem por objetivo induzir qualquer alteração de comportamento na prescrição ou toma de medicamentos.  PT-NON-00901 04/2021

In this episode, the third in a 3-part series on Ending the HIV Epidemic,  Judith Feinberg, MD, and  Kenneth Mayer, MD, discuss the important role of HIV pre-expsoure prophylaxis (PrEP) for preventing HIV infection among at-risk individuals and critical strategies for effective PrEP implementation among principle populations, including men who have sex with men and transgender women, heterosexual cisgender women, and people who inject drugs. Following their dialogue, the faculty field clinician questions on HIV prevention.Presenters:Judith Feinberg, MDProfessorAttending PhysicianDepartments of Medicine and Behavioral Medicine & PsychiatryWest Virginia University School of MedicineMorgantown, West VirginiaKenneth Mayer, MDInfectious Disease AttendingBeth Israel Deaconess Medical CenterProfessor of MedicineHarvard Medical SchoolMedical Research DirectorFenway Community HealthBoston, MassachusettsContent based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.Link to full program:http://bit.ly/3263Q1s

This episode covers the time course of HIV infections!

In this episode, the second in a 3-part series on Ending the HIV Epidemic, Jason Halperin, MD, MPH, and Aadia I. Rana, MD, discuss treatment as prevention, the critical infrastructure needed to implement rapid ART, the importance of routinely assessing for barriers to care, and real-time monitoring strategies that improve patient adherence and engagement. Following their dialogue, the faculty field clinician questions on HIV treatment and retention in care.Presenters:Jason Halperin, MD, MPHAssistant Professor of MedicineDepartment of Infectious DiseasesTulane UniversityInfectious Disease PhysicianCrescentCareNew Orleans, LouisianaAadia I. Rana, MDAssociate Professor of MedicineDivision of Infectious Diseases The University of Alabama at Birmingham 1917 ClinicBirmingham, AlabamaContent based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.Link to full program:https://bit.ly/3263Q1s

In this episode, the first in a 3-part series on Ending the HIV Epidemic, Lisa K. Fitzpatrick, MD, MPH, MPA, and David Malebranche, MD, MPH, discuss strategies to expand early HIV testing, maximize patient engagement in HIV care, navigate emerging clusters of HIV infection, and combat HIV-related stigma. Following their dialogue, the faculty field clinician questions on HIV diagnosis and management.  Presenters:Lisa K. Fitzpatrick, MD, MPH, MPAProfessorial LecturerDepartment of EpidemiologyGeorge Washington University School of Public HealthInterim Medical DirectorBlueRock CareWashington, DCDavid J. Malebranche, MD, MPHBoard-Certified Internal Medicine PhysicianHIV SpecialistContent based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.Link to full program:https://bit.ly/3263Q1s   

This episode covers HIV infection!

EPISODE OVERVIEW: Can you imagine a world without disease? A world where people suffering with medical death sentences and plagues are cured in a matter of weeks? It would be wonderful, right? Well, we may not be too far away from that world according to today's guest. Teaching computer classes at MIT at the age of 15, working in the tech industry for the first half of his career, and then moving into gene and cell therapy, Jeff Galvin and his team at American Gene Technologies (AGT) are leading the way in showing us how these two industries mirror one another, and finding the cure to what ails the world isn't far away. Check out this episode of the Remarkable People Podcast now and hear Jeff Galvin's Remarkable story of technology and hope!GUEST BIO: Jeff Galvin is the CEO and Founder of American Gene Technologies (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Dr. Roscoe Brady at NIH.FEATURED QUOTE(S): “The only thing necessary for the triumph of evil is for good men to do nothing.“ – Edmund Burke"We can now edit the "software" of the human cell (our DNA). Today 100's of companies are reprogramming human viruses to deliver updates to the human-computer. Today this technology is being used to cure incurable diseases, but the capabilities are doubling every year while the cost halves. In that environment, anything is possible; if you can dream it you can do it." - Jeff GalvinEPISODE PROUDLY SPONSORED BY:Pam Heinold, Better Homes and Gardens Real Estate – Pensacola, FL, https://bit.ly/PamHeinoldRPPSponsorBTK Innovations, https://BodyTemperatureKiosk.comSHOW NOTES, LINKS, CONTACT INFO, SPECIAL OFFERS, & RESOURCES MENTIONED:Sign up for the AGT Newsletter https://www.americangene.com/agt-newsletters/ Website:  https://www.americangene.com/Facebook: https://www.facebook.com/amerigene/LinkedIn: https://www.linkedin.com/company/1127234/Twitter: https://twitter.com/americangene/For more information about AGT or investment opportunities please contact: Norman Rogers, Business Development, email: nrogers@americangene.comHOW TO SUPPORT THE REMARKABLE PEOPLE PODCAST:Subscribe, Rate, and Review us in your favorite podcast directories & players

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.06.11.130666v1?rss=1 Authors: Walter, T., Young, J., Milienne-Petiot, M., Deben, D. S., Heaton, R., Letendre, S., Grelotti, D., Perry, W., Grant, I., Minassian, A. Abstract: HIV infection and methamphetamine (METH) use are highly comorbid and represent a significant public health problem. Both conditions are known to negatively impact a variety of brain functions. One brain function that may be affected by HIV and METH use is sensorimotor gating, an automatic, pre-conscious filtering of sensory information that is thought to contribute to higher order cognitive processes. Sensorimotor gating is often measured using prepulse inhibition (PPI), a paradigm that can be conducted in both humans and animals, thereby enabling cross-species translational studies. While previous studies suggest HIV and METH may individually impair PPI, little research has been conducted on the effects of combined HIV and METH on PPI. The goal of this cross-species study was to determine the effects of METH on PPI in the inducible Tat (iTat) mouse model of HIV and in people with HIV. PPI was measured in the iTat mouse model before, during, and after chronic METH treatment and after Tat induction. Chronic METH treatment decreased PPI in male but not female mice. PPI normalized with cessation of METH. Inducing Tat expression decreased PPI in male but not in female mice. No interactions between chronic METH treatment and Tat expression were observed in mice. In humans, HIV was associated with decreased PPI in both men and women. Furthermore, PPI was lowest in people with HIV who also had a history of METH dependence. Overall, these results suggest HIV and METH may additively impair early information processing in humans, potentially affecting downstream cognitive function. Copy rights belong to original authors. Visit the link for more info

Virtually eliminating the spread of HIV? Ten years ago ,the idea that we could end new cases of HIV spread through sexual contact would have been seen as a pipe dream. But, thanks to pharmaceutical advances, a new drug in the United States has the potential to make those dreams a reality. Pre-exposure prophylaxis, more commonly known as PrEP, is a pill that, if taken daily, can reduce the risk of contracting HIV from sexual contact by up to 99%. In 2014, the Centers for Disease Control and Prevention reported that 68% of new HIV cases can be attributed to men who have sex with other men. PrEP is meant only for people who are currently HIV negative and is targeted towards men who have sex with men as well as those that that have sex with men engaged in same sex activity. PrEP was among methods listed when the United States Department of Health and Human Services released a plan in 2019 with the goal of slowing the spread of HIV. While the drug is relatively new to the market, awareness

The US Navy granted its first waiver allowing a transgender service member to use their preferred gender. Injectable PrEP researchers made a major announcement. Plus, y'all need to get out of people's bedroom. We're not here for it. Send us questions, comments, and business inquiries, to hereforitpod@gmail.com We’re on Patreon! Join the #HereForItHive at www.patreon.com/HereForItPod Merch! https://hereforitshop.com/ Social Studies –  Injectable PrEP Study Ends Early with Good News https://www.globenewswire.com/news-release/2020/05/18/2034827/0/en/Long-Acting-Injectable-Cabotegravir-Is-Highly-Effective-for-the-Prevention-of-HIV-Infection-in-Cisgender-Men-and-Transgender-Women-Who-Have-Sex-With-Men.html Sexual Health – Chakrubs Follow us on social media @HereForItPod and hereforitpod.com www.instagram.com/hereforitpod www.twitter.com/hereforitpod www.facebook.com/hereforitpod Don't forget to leave us a comment or review on Apple Podcasts! Search our name in the Podcasts app, click the Reviews tab, click Write A Review. http://apple.co/2y6zmMi

In this podcast, Valerie Delpech, MBBS, MPH, speaks about her session at CROI 2020, which was focused on UK HIV epidemic and the programs that were implemented that helped reduce the number of HIV infections in the region. More at: www.consultant360.com/infectious-diseases

Professor Andrew Lever from the Department of Infectious Disease in Cambridge, joins us to discuss prevention of HIV, from pre-exposure prophylaxis, education and the limitations of vaccination, along with new and well-established methods of treating HIV infection.

How bringing loneliness to romantic and sexual encounters led to his HIV infection, Jonathan Larson researching his support group for material for the musical RENT, on being a teen whisperer and his new book "How To Raise An Elegant Teen: The ABCs of Gen Z Parenting" and more with motivational speaker Scott Fried Ep42 https://scottfried.com/ https://www.instagram.com/scottfried https://scottfried.com/shop/ https://scottfried.com/product/how-to-raise-an-elegant-teen/https://scottfried.com/product/a-private-midnight-a-teenagers-scrapbook-of-secrets/https://scottfried.com/product/if-i-grow-up-talking-with-teens-about-aids-love-and-staying-alive/

Dr. Dhruv Kazi is associate director of the Smith Center for Outcomes Research in Cardiology and director of the Cardiac Critical Care Unit at Beth Israel Deaconess Medical Center Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.S. Kazi, I.T. Katz, and A.K. Jha. PrEParing to End the HIV Epidemic — California’s Route as a Road Map for the United States. N Engl J Med 2019;381:2489-2491.

Rates of HIV diagnoses are falling in cities across the country like New York, Philadelphia and right here in Chicago. That’s the good news. The bad news: cases of the virus are cropping up more and more in rural areas like West Virginia and other parts of Appalachia. Reset sits down with Steven Thrasher, assistant professor at Northwestern University’s Medill School of Journalism, for more on this issue.  We also check in with Jill Hopkins, the host of the Morning Amp on WBEZ’s sister station Vocalo. She introduces us to some of the talented folks around the city that are being highlighted in Vocalo’s series “This Is What Chicago Sounds Like.”

+ Bitter lives and little hope: meeting sugarcane workers and their families in Guatemala +/ how a woman is making the best of living with HIV in a rural community in southern Africa.

Interview with John W Epling, MD, MSEd, Task Force member and co-author of Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement

Interview with Anthony S. Fauci, MD, author of Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles

JAMAevidence Podcast

Dr. Anupama Raghuram presents the "Basics of HIV Infection" by first discussing the epidemiology, pathogenesis and transmission of HIV infection. After, she presents the diagnosis, treatment, and prevention of HIV infection. Some items in this lecture may have come from the lecturer’s personal academic files or have been cited in-line or at the end of the lecture. For more information, see our citation page. Disclaimers©2016 LouisvilleLectures.org

Dr. Robert Goldstein is an instructor in medicine at Harvard Medical School and medical director of the Transgender Health Program at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. R.H. Goldstein, C.G. Streed, and S.R. Cahill. Being PrEPared — Preexposure Prophylaxis and HIV Disparities. N Engl J Med 2018;379:1293-1295.

En el programa de esta semana realizamos un estudio post-mortem de la epidemia de VIH que afecto al pueblo de Austin, Condado de Scott en Indiana, USA entre el 2014-2016 basado en la publicación de un articulo de análisis filodinamico de dicha epidemia publicado el 5 de octubre del 2017 en el Journal of Infectious Diseases.    Referencias:  Ellsworth M. Campbell y colaboradores. Detailed Transmission Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection in the United States. J Infect Dis. Octubre 5, 2017.     Phillip J Peters y colaboradores. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015. New Eng J med. July 21, 2016.    Michelle Van Handel y colaboradores. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. J Acquired Immune Deficiency Syndrome (JAIDS). Nov 1, 2016.   Frase de la Semana:   Es de John Rockefeller, 8 de julio de 1839 - 23 de mayo de 1937) fue un magnate de negocios de la industria petrolera estadounidense y filántropo. Considerado ampliamente como el estadounidense más acaudalado de todos los tiempos. Fue fundador de la Universidad de Chicago y del Rockefeller Institute for medical Research (hoy en día Rockefeller University) La frase dice: “Cada derecho implica una responsabilidad; cada oportunidad, una obligación, cada posesión, un deber".  

In this episode, our guest Dr. Joy Learman describes the underlying dynamics that can increase a woman's risk of being HIV-positive and failing to obtain treatment. She discusses her research involving contextual factors and personal experiences of HIV-positive African immigrant women. Dr. Learman emphasizes the need for support for at-risk groups and the development of policies that promote women's reproductive health and decrease their risk of HIV.

With a shortage of organs and waiting lists growing, the idea of transplanting organs from people who have diseases may become reality.

With organs for transplant in short supply, it's vital to talk to patients--even if they are elderly or have a disease like HIV--about the prospect of becoming donors, an ethicist says.

Dr. Anthony Fauci is director of the National Institute of Allergy and Infectious Diseases. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. A.S. Fauci and H.D. Marston. Ending the HIV-AIDS Pandemic - Follow the Science. N Engl J Med 2015;373:2197-9.

Tue, 16 Sep 2014 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/18549/ https://edoc.ub.uni-muenchen.de/18549/1/Eller_Leigh_Anne.pdf Eller, Leigh Anne ddc:610, ddc:600, Medizinische Fakultät

Tue, 16 Sep 2014 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/18688/ https://edoc.ub.uni-muenchen.de/18688/1/Adeyemi_Adedayo.pdf Adeyemi, Adedayo

This month, Virtual Mentor theme issue editor Kimberley Swartz, a medical student at the University of Florida College of Medicine, interviewed Dr. Gary Wang about the use of Truvada, approved in 2012 as a pre-exposure prophylaxis against HIV infection. Dr. Wang is an assistant professor of medicine in the Division of Infectious Diseases and Global Medicine at the University of Florida College of Medicine.

http://www.einstein.yu.edu - Researchers Drs. Yvette Calderon, Jason Leider and Ethan Cowan have found that community-based pharmacies can be effective locations for offering rapid HIV testing, diagnosing HIV, and connecting those who test positive with medical care quickly. Their paper published in the August 2013 edition of AIDS Patient Care and STDs. See accompanying release: http://www.einstein.yu.edu/news/releases/928/community-pharmacies-are-effective-locations-for-rapid-hiv-testing/

Sarah Rowland-Jones, Professor of Immunology, gives the 2013 Weatherall Lecture on understanding immunity to HIV infection.

AIDS Seminar Richard Moore, MD, MHS

Greg Towers, MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London - UK speaks on "Control of HIV Infection and Nuclear Targeting by Cellular Cyclophilins". This seminar has been recorded by ICGEB Trieste

Well, I thought, that sucks.

During this hour of POZIAM RADIO the hosts and guests will be discussing Meth and HIV/AIDS. With the astonishing rise in new infections in the gay community due to meth use, we felt it was important to dedicate a show to the subject. Our friends from www.tweaker.org will be joining us for the first part of the show to talk about Meth and how it affects our bodies,our sex and our overall lives. The second part of the show we will be joined by POZIAMer Greg B. who will be sharing his story of Meth use,Recovery and HIV.

Lecture 12 of 14: "HIV Infection." Harris Goldstein, M.D., director, Einstein-Montefiore Center for AIDS Research, professor of pediatrics and microbiology & immunology and the Charles Michael Chair in Autoimmune Diseases, delivers a lecture course in basic immunology organized by the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. The goal of this lecture series is to provide HIV investigators with a comprehensive course in immunology. (January 2010). View all slides in separate window to follow presentation more easily.

Lecture 12 of 14: "HIV Infection." Harris Goldstein, M.D., director, Einstein-Montefiore Center for AIDS Research, professor of pediatrics and microbiology & immunology and the Charles Michael Chair in Autoimmune Diseases, delivers a lecture course in basic immunology organized by the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. The goal of this lecture series is to provide HIV investigators with a comprehensive course in immunology. (January 2010). View all slides in separate window to follow presentation more easily.

Audrey Ceschia discusses issue highlights, including impact of HIV infection on cancer risk.

Host: Mark Nolan Hill, MD Guest: Jeffrey Klausner, MD, MPH Detection and treatment of HIV in the United States has improved dramatically since the peak of the epidemic here in the 1980s, but there is far more work to be done. HIV transmission is one area of heightened concern, particularly those cases spread by newly infected persons who remain undiagnosed. Though tests are available to diagnose HIV in the acute phase, many experts believe we must improve these tests to really make headway in reducing the incidence of HIV in the United States. Dr. Jeffrey Klausner, a deputy health officer and director of the STD Prevention and Control Services Section at the San Francisco Department of Public Health, joins host Dr. Mark Nolan Hill to lay out the path toward progress in detecting acute cases of HIV infection. Newer, more effective tests are available, but must be adopted around the United States, and as Dr. Klausner looks ahead, a point-of-care rapid exam, though still in development, could eventually change the paradigm for early-stage HIV detection.

Harrisons Online Update

Guest: Robert Bailey, PhD, MPH Host: Larry Kaskel, MD New research reveals that male circumcision could reduce HIV infection rates by up to 60 percent, which could prevent 5.7 million new cases and 3 million deaths over 20 years in sub-Saharan Africa. Dr. Robert Bailey, professor of epidemiology at the University of Illinois, Chicago, School of Public Health, discusses his research findings with host Dr. Larry Kaskel, highlighting HIV infection rates in areas of Africa where the male population is circumcised, and explaining the mechanism by which HIV infection may occur in uncircumcised men.

Fri, 1 Jan 1993 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7908/1/zidovudine_in_persons_7908.pdf Jänike, F.; Bogner, Johannes R.; Mertins, P.; Goos, M.; Fiddian, A. Paul; Stevens, John W.; Gonzalez-Lahoz, Juan; Melville, Rex L.; Stingl, Georg; Bruun, Johan N.; Goebel, Frank-Detlef; Millard, Judith; Clumeck, Nathan; Kroon, Susanne; Gatell, Jose M.; Cooper, David A.

Fri, 1 Jan 1993 12:00:00 +0100 https://epub.ub.uni-muenchen.de/8040/1/impairment_of_colour_contrast_sensitivity_and_neutroretinal_dysfunction_8040.pdf Goebel, Frank-Detlef; Klauß, Volker; Berninger, Thomas; Hammel, Gertrud; Bogner, Johannes R.; Kronawitter, Ursula; Geier, Stephan A.